Freenome (NASDAQ:FRNM) Upgraded to “Strong-Buy” at Guggenheim

Guggenheim upgraded shares of Freenome (NASDAQ:FRNM) to a strong-buy rating in a research note published on Thursday morning, MarketBeat Ratings reports. Guggenheim currently has $21.00 price target on the stock.

FRNM has been the subject of several other reports. Leerink Partners assumed coverage on Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 price objective for the company. TD Cowen started coverage on shares of Freenome in a report on Tuesday. They issued a “buy” rating and a $17.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Freenome in a research note on Monday. They set a “buy” rating and a $17.00 price target for the company. Finally, BTIG Research started coverage on shares of Freenome in a research note on Monday. They issued a “buy” rating and a $17.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

Freenome Stock Down 0.9%

Freenome stock opened at $13.51 on Thursday. The stock has a market capitalization of $110.24 million, a PE ratio of -225.13 and a beta of 0.35. Freenome has a fifty-two week low of $9.97 and a fifty-two week high of $14.26.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.